140 related articles for article (PubMed ID: 32009778)
1. A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects.
Kim E; Park KR; Jang IJ; Yu KS; Lee S
Drug Des Devel Ther; 2019; 13():3879-3885. PubMed ID: 32009778
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study.
Yang E; Yoo H; Jang IJ; Yu KS; Lee S
Drug Des Devel Ther; 2021; 15():651-658. PubMed ID: 33628012
[TBL] [Abstract][Full Text] [Related]
3. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
Park SI; Lee H; Oh J; Lim KS; Jang IJ; Kim JA; Jung JH; Yu KS
Drug Des Devel Ther; 2015; 9():729-36. PubMed ID: 25678778
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination
.
Lee SW; Park SI; Lee S; Chung JY; Yu KS
Int J Clin Pharmacol Ther; 2019 Feb; 57(2):117-124. PubMed ID: 30574864
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects.
Cho YS; Lee SH; Lim HS; Bae KS
J Korean Med Sci; 2018 Oct; 33(41):e258. PubMed ID: 30288156
[TBL] [Abstract][Full Text] [Related]
6. Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers.
Choi HY; Noh YH; Kim YH; Kim MJ; Lee SH; Kim JA; Kim B; Lim HS; Bae KS
Int J Clin Pharmacol Ther; 2014 May; 52(5):381-91. PubMed ID: 24495314
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects.
Choi HY; Lim HS; Kim YH; Jeon HS; Kim MJ; Lee SH; Jung JH; Lee YK; Kim HJ; Bae KS
Curr Med Res Opin; 2015 Feb; 31(2):229-41. PubMed ID: 25350224
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of a fixed-dose combination of gemigliptin/metformin sustained release 25/500 mg compared to the loose combination in healthy male subjects.
Jin X; Kim E; Huh KY; Hwang I; Cho JY; Yu KS; Lee S
Transl Clin Pharmacol; 2020 Mar; 28(1):43-54. PubMed ID: 32274380
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan/Rosuvastatin with Concomitant Administration of Amlodipine/Losartan and Rosuvastatin in Healthy Volunteers.
Yoon DY; Park SI; Jung JA; Kim YI; Jang IJ; Chung JY
Drug Des Devel Ther; 2020; 14():661-668. PubMed ID: 32109991
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects.
Kang WY; Seong SJ; Ohk B; Gwon MR; Kim BK; Cho S; Shim WS; Lee KT; Kim EH; Yang DH; Lee HW; Yoon YR
Drug Des Devel Ther; 2018; 12():3607-3615. PubMed ID: 30464392
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial.
Bae JC; Min KW; Kim YH; Kim KA; Hong EG; Park CY; Han S; Cha BS
Diabetes Obes Metab; 2019 Jan; 21(1):103-111. PubMed ID: 30084112
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of fimasartan, amlodipine, and rosuvastatin using partial replicated design in healthy adult subjects.
Oh M; Ghim JL; Park SE; Kim EY; Shin JG
Drug Des Devel Ther; 2018; 12():1157-1164. PubMed ID: 29780236
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Pharmacokinetics and Safety of a Fixed-dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects.
Min KL; Park MS; Jung J; Chang MJ; Kim CO
Clin Ther; 2017 Sep; 39(9):1799-1810. PubMed ID: 28803122
[TBL] [Abstract][Full Text] [Related]
14. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects.
Son H; Roh H; Lee D; Chang H; Kim J; Yun C; Park K
Clin Ther; 2013 Jul; 35(7):915-22. PubMed ID: 23810276
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of a telmisartan/rosuvastatin fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects.
Chae DW; Son M; Kim Y; Son H; Jang SB; Seo JM; Nam SY; Park K
Int J Clin Pharmacol Ther; 2015 Oct; 53(10):883-9. PubMed ID: 26329347
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Pharmacokinetics of a Fixed-Dose Combination of Rosuvastatin/Metformin Sustained-Release (10/1000 mg) and Separate Tablets in Healthy Male Subjects.
Huh KY; Kim E; Lee H; Jeon I; Suh H; Lee J; Lee Y; Yu KS; Lee S
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):207-213. PubMed ID: 32579298
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of amlodipine, olmesartan, and rosuvastatin in healthy adult subjects.
Oh M; Shin JG; Ahn S; Kim BH; Kim JY; Shin HJ; Shin HJ; Ghim JL
Drug Des Devel Ther; 2019; 13():991-997. PubMed ID: 31114155
[No Abstract] [Full Text] [Related]
19. Pharmacokinetic and bioequivalence study comparing a candesartan cilexetil/rosuvastatin calcium fixed-dose combination with the concomitant administration of candesartan cilexetil and rosuvastatin calcium in healthy Korean subjects
.
Park DB; Jang K; Lee JW; Park CW; Lee BH; Kim MG; Jeon JY
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):286-294. PubMed ID: 28079517
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers.
Choi HY; Kim YH; Kim MJ; Lee SH; Bang K; Han S; Lim HS; Bae KS
Drugs R D; 2014 Sep; 14(3):165-76. PubMed ID: 24962635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
